Moreover, we recently showed that CSF HoxB3 and YKL-40 levels had a higher predictive value than serum HoxB3 and YKL-40 levels in the evaluation of disability progression in MS patients [20]. This evidence concerns the gene HOXB3 and myeloid sarcoma.